Roche/Genentech win Avastin OK in advanced cervical cancer
This article was originally published in Scrip
Executive Summary
The FDA on 14 August gave its blessing to Roche US subsidiary Genentech to market Avastin (bevacizumab) plus paclitaxel and cisplatin or paclitaxel and topotecan to treat patients with persistent, recurrent or metastatic cervical cancer – once gain expanding the drug's US labeling.